HACKENSACK, N.J., Nov. 8 /PRNewswire-FirstCall/ -- DOV Pharmaceutical, Inc. announced today that its CFO, Barbara Duncan, will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on Wednesday, Nov. 9, 2005. Her presentation, scheduled to begin at 9:45 a.m. EST at The New York Palace Hotel in New York City, will discuss data from the Company’s late stage clinical development programs and updates about its preclinical pipeline.
Ms. Duncan’s presentation will be archived and available on the investor relations section of DOV’s Web site: http://www.dovpharm.com after the conference for 90 days.
About DOV
DOV is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of novel drug candidates for central nervous system and other disorders, including cardiovascular, that involve alterations in neuronal processing. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, pain and depression. Our partner Neurocrine has filed two NDAs for the use of DOV’s compound indiplon for the treatment of insomnia.
DOV Pharmaceutical, Inc.
CONTACT: Alan Beckhard, Manager, Investor Relations and CorporateCommunications of DOV Pharmaceutical, Inc., +1-201-968-0980
Web site: http://www.dovpharm.com/
